Education
About Us
Working with TipRanks
Follow Us
Ab Science (ABSCF)
:ABSCF
ABSCF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $1.60
Previous CloseN/A
Volume100.00
Average Volume (3M)0.00
Market Cap
$94.68M
Enterprise Value$47.53M
Total Cash (Recent Filing)$7.99M
Total Debt (Recent Filing)$18.47M
Price to Earnings (P/E)―
Beta-235106.03
Next Earnings
Sep 30, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding61,430,130
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue44.33
Enterprise Value/Gross Profit81.80
Enterprise Value/Ebitda-7.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AB Science SA News
ABSCF FAQ
What was Ab Science’s price range in the past 12 months?
Ab Science lowest stock price was $0.80 and its highest was $1.60 in the past 12 months.
What is Ab Science’s market cap?
Ab Science’s market cap is $94.68M.
When is Ab Science’s upcoming earnings report date?
Ab Science’s upcoming earnings report date is Sep 30, 2025 which is in 53 days.
How were Ab Science’s earnings last quarter?
Ab Science released its earnings results on May 12, 2025. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.07.
Is Ab Science overvalued?
According to Wall Street analysts Ab Science’s price is currently Overvalued.
Does Ab Science pay dividends?
Ab Science does not currently pay dividends.
What is Ab Science’s EPS estimate?
Ab Science’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ab Science have?
Ab Science has 61,430,130 shares outstanding.
What happened to Ab Science’s price movement after its last earnings report?
Ab Science reported an EPS of -$0.07 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ab Science?
Currently, no hedge funds are holding shares in ABSCF
Company Description
Ab Science
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Sensorion SAS
―
ABL Diagnostics SA
―
Ownership Overview
―
Insiders
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---